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Insulin secretionAbstract The prevalence and magnitude of childhood and adult obesity and diabetes are increas-
ing dramatically. FOXO 1a and FOXO 3a will be evaluated in this study, in an effort to identify
genetic polymorphisms in potential candidate genes that may be associated with body mass index
(BMI), and metabolic syndrome (MS). Also to assess whether there is a relation between insulin
sensitivity, and genotype, we will test the relation between fasting insulin, glucose, insulin resistance,
insulin secretion and genotype.
A total number of 248 presenting normal, overweight and obese individuals were recruited; 100
children and 148 adults of both sexes. They were divided by body mass index as follows, normal,
overweight and obese. Lipid proﬁle, fasting glucose and insulin HOMA-IR and HOMA-b index
and RT-PCR for FOXO 1a and FOXO 3a were performed.
An association was found among the studied group (children and adults) as regards foxo3a gene
polymorphism and HOMA IR, HOMA B index and T-cholesterol (P= 0.022, 0.011 and 0.028,
respectively), while there was only an association between LDL-C and foxo1a gene polymorphism
among the studied group of children and adults (P= 0.023).
128 S. Ragab et al.In this study we demonstrated that FOXO3a mutant is correlated with HOMA-IR (marker of
insulin resistance), HOMA-B index (marker of insulin secretion) and total cholesterol while as
regards FOXO1a there was only an association between LDL cholesterol and mutant type of
FOXO1a.
ª 2014 Production and hosting by Elsevier B.V. on behalf of Academy of Scientific Research &
Technology. Open access under CC BY-NC-ND license.1. Introduction
Metabolic syndrome is the clustering of heterogeneous
metabolic abnormalities, mainly obesity, dyslipidemia insulin
resistance, hyperglycemia and hypertension that may cause
an increased risk of cardiovascular morbidity and mortality
[1].
Obesity is characterized by a body mass index (BMI) of
over 30 kg/m2. The prevalence of obesity will rise to approxi-
mately 700 million people worldwide in 2015 [2].
It is closely associated with a number of pathological disor-
ders, such as non-insulin-dependent diabetes, hypertension,
cancer, gallbladder disease and atherosclerosis [3]. Obesity is
a multifactorial disease with genetic and environmental ori-
gins, resulting from an imbalance between energy intake and
expenditure [4]. A large number of genetic association studies
have suggested that polymorphic variants in genes that regu-
late energy metabolism, such as proliferator-activated recep-
tor-c, b3-adrenergic receptor, leptin receptor, glucocorticoid
receptor, and tumor necrosis factor, may predispose individu-
als to become obese [5]. Additionally, obesity induces insulin
resistance, and a high fat diet is its major cause as well as insu-
lin resistance. This suggests a close association between insulin
signaling and obesity [6].
FOXO proteins are involved in several pathways responsi-
ble for cell metabolism, onset of diabetes mellitus and diabetic
complications; however other studies suggest that they are clo-
sely linked to the prevention of these complications through
the preservation of cellular energy reserves and mitochondrial
integrity [7].
The family of Forkhead Box 0 (FOXO) transcription fac-
tors, in particular, FOXO1, FOXO 3a, and FOXO4, has been
implicated to play a critical role in the control of proliferative
and apoptotic processes. Initial work has linked metabolic
insulin signaling and life-span extension with these transcrip-
tion factors in multiple species [8].
Genome-wide association study in the Framingham popu-
lation suggested that eight SNPs (Single Nucleotide Polymor-
phisms) are strongly associated with the age of death. Among
these eight, two SNPs, are located in the FOXO1A gene. In
addition, FOXO1A and FOXO3A are critical downstream
molecules of AKT1 and are inactivated by AKT1-mediated
insulin signaling pathways that regulate the cell cycle, apopto-
sis, stress resistance and metabolism [9].
FOXO 1a and FOXO 3a will be evaluated in this study, in
an effort to identify genetic polymorphisms in potential candi-
date genes that may be associated with body mass index, and
metabolic syndrome.
Also to assess whether there is a relation between insulin
sensitivity, and genotype, we will test the relation between fast-
ing insulin, glucose, insulin resistance, insulin secretion and
genotype.2. Materials and methods
2.1. Patients
A total number of 248 presenting normal, over weight and
obese individuals were recruited from NRC pediatrics and
internal medicine clinics, Abou El-Rish Hospital, Cairo Uni-
versity and Ain Shams Hospital which included 100 children
and 148 adults.
They were divided by body mass index (BMI) as follows,
normal and over weight (obese are included within this
group).
The exclusion criteria were: (1) the presence of type II dia-
betes or of ﬁrst-grade relatives with type II diabetes, (2) hypo-
thyroidism, (3) the presence of coronary artery disease (CAD),
chronic kidney and liver diseases, also collagen diseases, (4)
patients on corticosteroid medication and (5) obesity as a part
of syndrome. In all subjects, a complete medical history
was obtained using questionnaire. History taking included
questions about smoking habits, history of hypertension and
type II diabetes and current medication used. Diagnosis of
type II diabetes was based on the history of hypoglycemic
treatment and/or conﬁrmed fasting blood glucose >126 mg/
dl (7.0 mmol/L). The metabolic syndrome was diagnosed in
children and adults according to International Diabetes Feder-
ation (IDF) criteria [10] (Table I).
Diagnosis of hypertension was based on the presence of ele-
vated systolic (>140 mmHg) and/or diastolic (>90 mmHg)
blood pressure, and/or the current use of antihypertensive
medications.
Body weight and height were measured, body mass index
(BMI) was calculated as weight in kilograms divided by height
in meters squared.2.2. Laboratory measurements
Blood samples after 12 h fasting were collected from all indi-
viduals by a sterile venipuncture and are divided as follows:
two milliliters of blood in a sterile EDTA containing vacutain-
er for DNA extraction using DNA extraction kits (QIAGEN);
three milliliters of blood in a plain vacutainer and allowed to
clot for 30 min before centrifugation for 10 min. Then the sera
separated from the clotted samples are used for lipid proﬁle
(total cholesterol, HDL, LDL, VLDL and triglycerides) and
fasting glucose. All were measured by an Olympus AU 400
auto analyzer. Insulin was measured by the chemiluminescence
technique (on Immulite auto analyzer). Insulin resistance was
calculated by the homeostatic model assessment-insulin resis-
tance (HOMA-IR) using the following formula [9]: HOMA-
IR = fasting insulin (mU/L) X plasma glucose (mmol/L)/
22.5. Insulin secretion (b-cell function) was calculated by the
Table I Deﬁnition criteria for metabolic syndrome in children, adolescents and adults [10].
Ages (years) IDF criteria
6-9 10-15 >15 (adult criteria)
Waist circumference P90th percentile
forage (MS as entity
is not diagnosed)
P90th percentile or adult cut-oﬀ if
lower
P94 cm for Europid males, P80 cm for females
Blood pressure Systolic P130 or diastolic
P85 mm Hg
Systolic P130 or diastolic >85 mm Hg or
treatment of previously diagnosed hypertension
Triglycerides P1.7 mmol/L (P150 mg/dL) P1.7 mmol/L (P150 mg/dl) or speciﬁc treatment
for high triglycerides
HDL-C 61.03 mmol/L (640 mg/dL) <1.03 mmol/L (<40 mg/dL) in males and
<1.29 mmol/L (<50 mg/dL) in females or
speciﬁc treatment for low HDL-C
Fasting glucose 5.6 mmol/L (100 mg/dL) 5.6 mmol/L (100 mg/dL) or known T2DM
For the diagnosis of metabolic syndrome, central obesity and 2 of 4 other components must be present.
IDF: International Diabetes Federation; T2DM: Type 2 Diabetes Mellitus.
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using the following formula [9]: HOMA-b= 20 · fasting insu-
lin level (lIU mol)/fasting glucose 3.5.2.3. Genotype analysis of foxo gene
Two milliliters of blood in a sterile EDTA containing vacu-
tainer was obtained from each subject and stored at 80 C
until DNA extraction. Genomic DNA was isolated from blood
of overweight, obese individuals and controls, followed by RT-
PCR Assay.
2.4. Extraction of DNA
Extraction of DNA was done from whole blood (collected in
vacutainer EDTA tubes). The QIAamp Blood Kit was used
for DNA extraction (Cat. No. 51106; Qiagen Inc., Valencia,
CA, http://www.qiagen.com).
a. The samples were equilibrated to room temperature.
b. Heat block was heated to 56 C.
c. Buffer AW1, Buffer AW2, and QIAGEN protease
ensured that they had been prepared according to the
instructions.
d. All centrifugation steps were carried out at room
temperature.
e. 200 ll of the whole blood yielded 3–12 lg of DNA.
2.5. Procedure
1. 200 ll whole blood was added to 20 ll QIAGEN prote-
ase, and 200 ll Buffer AL into a 1.5 ml low binding
microcentrifuge tube and mixed by vortexing.
2. Incubated at 56 C for 10 min.
3. Spinned down brieﬂy to remove drops from the inside of
the tube.
4. 200 ll of 96–100% ethanol was added and mixed by
vortexing.
5. The mixture was carefully applied from the step above
to a QIAamp spin column, centrifuged for 1 min in
the QIAamp spin column and was carefully openedand operated at full speed (15,000 g). The tube contain-
ing the ﬁltrate was discarded.
6. The DNA would be bound to the ﬁlters in the spin col-
umns. Column was placed in a clean 2 ml collection
tube.
7. QIAamp spin column was opened and 500 ll Buffer
AW1 was added without hitting the rim. The cap was
closed and centrifuged for 1 min at full speed. QIAamp
spin column was placed in a clean 2 ml collection tube.
8. The QIAamp spin column was carefully opened and was
added 500 ll Buffer AW2. The cap was closed and cen-
trifuged in the QIAamp column for 3 min at maximum
speed.
9. The 2 ml collection tube containing the ﬁltrate was dis-
carded, the QIAamp spin column was placed in a new
collection tube and spun for 1 min to remove residual
buffer AW2.
10. The spin column was placed in a clean 1.5 ml low bind-
ing microcentrifuge tube. Two hundred microliters Buf-
fer AE or distilled water was added to the spin column,
incubated at room temperature for 5 min to elute the
DNA and centrifuged 1 min at full speed. One microliter
of extracted DNA was used for a 50 ll PCR.
11. Stored at 4 C.
2.6. RT-PCR assay
Using light cycler system to detect FOXO 1a and FOXO 3a
gene mutation (Roche Diagnostics, Mannheim, Germany)
according to manufacturer’s instructions, PCR ampliﬁcation
was performed using FOXO 1a and FOXO 3a primer pairs:
FOXO la: Forward 50-CTG GCT CTC ACA GCA ATG
AT-30
Reverse: 50-CACCAT AGA ATG CAC ATCCC-30
FOXO 3a: Forward 50-GGG GAG TTT GGT CAA TCA
GA-30
Reverse: 50-TTT GCA TAG ACT GGC TGACG-30
After ampliﬁcation, point mutations were detected by a
melting-curve analysis. The result of the melting curve analysis
yielded three characteristic curves: a curve with a single early
130 S. Ragab et al.peak (homozygous wild type), a curve with a single late peak
(homozygous mutant) and a curve with two peaks (heterozy-
gous genotype).
2.7. Statistical analysis
The standard computer program SPSS for Windows, release
12.0 (SPSS Inc., USA) was used for data entry and analysis.
All numeric variables were expressed as mean ± standard
error of mean (SE). Comparison of different variables in var-
ious groups was done using Student’s t test and Mann–Whit-
ney test for normal and nonparametric variables, respectively.
Pearson’s and Spearman’s correlation tests (r= correlation
coefﬁcient) were used for correlating normal and non-paramet-
ric variables, respectively. Mean values between different
groups were compared using one way ANOVA test. A proba-
bility (p) less than 0.05 (<0.05) is considered signiﬁcant.
3. Results
Table 1 shows comparison between normal and obese individ-
uals as regards systolic blood pressure, diastolic blood pres-
sure, HOMA IR, HOMA B Index, T-cholesterol,
triglycerides, HDL-C and LDL-C in children and adults.
There is a signiﬁcant increase in insulin secretion among obese
children represented by HOMA B Index (P= 0.26), while in
adults there is a signiﬁcant increase in systolic blood pressureTable 2 Descriptive characteristic of the subjects with metabolic sy
Children
No MS (n= 23) MS (n= 3)
Systolic blood pressure 106.6 ± 11.1 110.0 ± 20.0
Diastolic blood pressure 69.6 ± 10.0 65.0 ± 15.0
HOMA-IR .13 ± .08 .17 ± .07
HOMA-B 72.5 ± 34.6 96.3 ± 24.5
Total cholesterol (mg/dl) 175.5 ± 33.0 194.6 ± 33.2
Triglycerides (mg/dl) 99.5 ± 28.7 164.3 ± 6.1
HDL cholesterol (mg/dl) 43.3 ± 9.1 41.6 ± 14.5
LDL cholesterol (mg/dl) 112.3 ± 27.9 120.0 ± 29.3
MS: metabolic syndrome, HOMA-IR: homeostatic model assessment-
function.
* Signiﬁcance = P< 0.05.
Table 1 Descriptive characteristic of the study subjects.
Children
Normal (n= 42) Overweight (n= 58)
Age (years) 9.05 ± 3.06 12.1 ± 3.1
Systolic blood pressure 101.6 ± 8.1 106.1 ± 12.0
Diastolic blood pressure 66.8 ± 6.5 67.9 ± 10.4
HOMA-IR 0.12 ± .07 0.16 ± 0.10
HOMA-B 103.7 ± 84.9 175.4 ± 187.5
Total cholesterol (mg/dl) 173.1 ± 30.0 168.3 ± 34.8
Triglycerides (mg/dl) 99.0 ± 31.6 112.7 ± 51.7
HDL cholesterol (mg/dl) 41.7 ± 8.3 43.2 ± 8.5
LDL cholesterol (mg/dl) 111.3 ± 29.7 103.4 ± 33.3
HOMA-IR: homeostatic model assessment-insulin resistance, HOMA-B:
* Signiﬁcance = P< 0.05.(P= 0.00), diastolic blood pressure (P= 0.001), HOMA IR
(P= 0.002), T-cholesterol (P= 0.012), triglycerides
(P= 0.001) and LDL-C (P= 0.003) among obese individuals
when compared by normal weight ones.
Table 2 shows comparison regarding the presence of meta-
bolic syndrome (MS) in children and adults. A highly signiﬁ-
cant correlation is present in children diagnosed with MS as
regards just triglycerides (P= 0.001), while in adults there is
a strong signiﬁcant correlation in those diagnosed with MS
as regards systolic blood pressure (P= 0.000), diastolic blood
pressure (P= 0.012), T-cholesterol (P= 0.005), triglycerides
(P= 0.00) and LDL-C (P= 0.015). Correlation between
adults diagnosed with MS as regards HOMA IR is also signif-
icant (P= 0.047).
Spearman correlation in the studied children group
revealed a signiﬁcant correlation between the HOMA IR and
each of the following; BMI (r= 0.437; P= 0.037), HOMA
B Index (r= 0.715; P= 0.000), T-cholesterol (r= 0.525;
P= 0.006), triglycerides (r= 0.421; P= 0.032) and LDL-C
(r= 0.456; P= 0.019). Also a signiﬁcant correlation was
found between BMI and triglycerides (r= 0.428; P= 0.042),
T-cholesterol and HDL-C (r= 0.391; P= 0.048) (Table 3).
Pearson correlation in the studied adult group showed a
signiﬁcant correlation between the HOMA IR and each of
the following; HOMA B Index (r= 0.734; P= 0.000), T-cho-
lesterol (r= 0.290; P= 0.008), and LDL-C (r= 0.272;
P= 0.014). Also a signiﬁcant correlation was found betweenndrome.
Adult
P value No MS (n= 52) MS (n= 35) P value
.681 111.36 ± 12.8 124.31 ± 14.8 .000*
.505 73.03 ± 8.7 79.31 ± 10.3 .012*
.503 1.20 ± 2.1 2.2 ± 2.41 .047*
.264 88.6 ± 115.6 78.0 ± 71.5 .650
.355 195.1 ± 44.1 222.6 ± 49.1 .005*
.001* 99.1 ± 27.2 153.9 ± 70.3 .000*
.785 46.4 ± 11.1 42.0 ± 10.8 .057
.661 132.1 ± 35.8 152.4 ± 152.4 .015*
insulin resistance, HOMA-B: homeostatic model assessment-b-cell
Adult
P value Normal (n= 42) Overweight (n= 106) P value
– 27.4 ± 8.4 41.8 ± 13.3 –
068 107.1 ± 10.8 119.7 ± 15.1 .000*
.576 70.2 ± 7.1 77.3 ± 8.9 .001*
.093 0.7 ± 0.6 2.5 ± 2.5 .002*
.026* 80.9 ± 102.2 99.6 ± 124.9 .560
.506 170.7 ± 41.4 193.0 ± 51.6 .012*
.122 83.1 ± 45.3 112.1 ± 51.5 .001*
.418 43.3 ± 9.8 46.8 ± 12.0 .083
.255 118.3 ± 31.2 146.1 ± 39.3 .003*
homeostatic model assessment-b-cell function.
Table 3 Spearman correlation coefﬁcients of variables in the analysis regarding children.
BMI Systolic
blood
pressure
Diastolic
blood
pressure
HOMAIR HOMAB Total
cholesterol
Triglycerides HDL
cholesterol
LDL
cholesterol
BMI
Correlation coeﬃcient
P value
1.0 .336
.160
.062
.801
.437*
.037
.330
.124
.251
.248
.428*
.042
.211
.333
.224
.305
Systolic blood pressure
Correlation coeﬃcient
P value
– 1.0 .607*
.006
.148
.557
.224
.371
.109
.666
.058
.819
.272
.275
.000
1.000
Diastolic blood pressure
Correlation coeﬃcient
P value
– – 1.0 .052
.838
.052
.837
.259
.300
.151
.549
.114
.653
.284
.254
HOMA-IR
Correlation coeﬃcient
P value
– – – 1.0 .715*
.000
.525*
006
.421*
.032
.030
.883
.456*
.019
HOMA-B
Correlation coeﬃcient
P value
– – – – 1.0 .041
.842
.322
.108
.250
.218
.050
.809
Total cholesterol
Correlation coeﬃcient
P value
– – – – – 1.0 .329
.101
.391*
.048
.958
.000
Triglycerides
Correlation coeﬃcient
P value
– – – – – – 1.0 .298
.139
.233
.253
HDL cholesterol
Correlation coeﬃcient
P value
– – – – - – – 1.0 .238
.242
LDL cholesterol
Correlation coeﬃcient
P value
– – – – – – – – 1.0
BMI: body mass index, HOMA-IR: homeostatic model assessment-insulin resistance, HOMA-B: homeostatic model assessment-b-cell function.
* Signiﬁcant correlation = P< 0.05.
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(r= 0.450; P= 0.000, r= 0.346; P= 0.000; r= 0.942;
P= 0.000, respectively), as well as a correlation was found
between diastolic blood pressure, T-cholesterol and LDL-C
(r= 0.371; P= 0.003; r= 0.334; P= 0.14, respectively)
(Table 4).
The overall number of individuals that underwent genotyp-
ing for Foxo1a was 95 (24 children and 71 adults), all studied
children had no mutation in foxo 1a while 9.85% of adults
revealed homozygous mutation and just only 2.81% of the
studied adults showed heterozygous mutation (Table 5). One
hundred and seven subjects underwent Foxo3a genotyping
(23 children and 84 adult), homozygous and heterozygous
mutation in foxo3a in children were the same (8.69%), while
8.33% of adults were homozygous mutants for foxo3a gene
and 2.38% were heterozygous mutants (Table 5).
An association was found among the studied group (chil-
dren and adults) as regards foxo3a gene polymorphism and
HOMA IR, HOMA B Index and T-cholesterol (P= 0.022,
0.011 and 0.028, respectively), while there was only an associ-
ation between LDL-C and foxo1a gene polymorphism among
the studied group of children and adults (P= 0.023) (Table 6).4. Discussion
Pancreatic b cells are located in the islets of Langerhans which
constitute the endocrine compartment of the pancreas. B-cellsproduce insulin and secrete it in response to elevations in cir-
culating blood glucose and to other signaling molecules, pro-
viding a key contribution to glucose homeostasis and to the
coordination of metabolism within the body. FOXO factors
are expressed in b cells, and many pathways that have been
shown to regulate FOXO function in other tissues are active
in b cells [8].
FOXO1 is the most predominantly expressed FOXO factor
in isolated mice islets as well as in the b TC-3 b cell line. In
mice islets, FOXO3 is expressed at a lower level; while FOXO4
is apparently undetectable [11]. FOXO1 has also been shown
to be expressed in isolated human islets [12]. Interestingly, fox-
o1mRNA levels are more elevated in islets of diabetic when
compared with non-diabetic patients, but the reason for this
is unknown [8]. FOXO proteins are involved in several path-
ways responsible for cell metabolism, onset of diabetes mellitus
and diabetic complications [9]. The range of applicable disease
processes that can be affected by aberrant FOXO protein func-
tion appears to be limitless and might arise from the observa-
tion that FOXO proteins can both enhance as well as repress
gene function in processes that involve cell apoptosis, cell cycle
regulation and cell senescence. As a result, it must be recog-
nized that simplistic recipes to modulate FOXO proteins can
become a double-edge sword to yield both beneﬁcial and det-
rimental biological outcomes [9].
In this study we demonstrated that FOXO3a mutant is cor-
related with HOMA-IR, HOMA-B index (marker of insulin
secretion) and total cholesterol while as regards FOXO1a there
Table 4 Pearson correlation coefﬁcients of variables in the analysis regarding adults.
BMI Systolic
blood
pressure
Diastolic
blood
pressure
HOMAIR HOMAB Total
cholesterol
Triglycerides HDL
cholesterol
LDL
cholesterol
BMI
Correlation coeﬃcient
P value
1.0 .317
.012
.172
.182
.206
.105
.064
.614
.109
.320
.172
.115
.042
.704
.142
.256
Systolic blood pressure
Correlation coeﬃcient
P value
– 1.0 .782*
.000
.085
.527
.074
.575
.239
.061
.225
.079
.212
.098
.141
.277
Diastolic blood pressure
Correlation coeﬃcient
P value
– – 1.0 .075
.575
.062
.640
.371*
.003
.134
.301
.234
.067
.334*
.009
HOMA-IR
Correlation coeﬃcient
P value
– – – 1.0 .734*
.000
.290*
.008
.117
.290
.050
.653
.272*
.014
HOMA-B
Correlation coeﬃcient
P value
– – – – 1.0 087
.426
.071
.515
.069
.531
.161
.142
Total cholesterol
Correlation coeﬃcient
P value
– – – – – 1.0 .450*
.000
.346*
.000
.942*
.000
Triglycerides
Correlation coeﬃcient
P value
– – – – – – 1.0 .071
.470
.193
.074
HDL cholesterol
Correlation coeﬃcient
P value
– – – – – – – 1.0 .169
.118
LDL cholesterol
Correlation coeﬃcient
P value
– – – – – – – – 1.0
BMI: body mass index, HOMA-IR: homeostatic model assessment-insulin resistance, HOMA-B: homeostatic model assessment-b-cell function.
* Signiﬁcant correlation = P< 0.05.
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type of FOXO1a.
Clinical studies suggest that FOXO proteins play a signiﬁ-
cant role in diabetes mellitus, oxidative stress, immune system
function and cancer. In a study of 734 individuals, polymor-
phism of FOXO3a displayed a signiﬁcant association with
body mass index such that the highest body mass index was
present in individuals homozygous for this allele [13]. Analysis
of the genetic variance in FOXO1a and FOXO3a on metabolic
proﬁles, age-related diseases, fertility, fecundity and mortality
have observed higher HbA1c levels and increased mortality
risk associated with speciﬁc haplotypes of FOXO1a. In addi-
tion, there was an increased risk of stroke in two haplotypes
of FOXO3a, which suggests an association with cerebral oxi-
dative stress disorders such as diabetes and stroke with
FOXO1a and FOXO3a [14].Table 5 Number and percent of foxo1a and foxo3a gene
polymorphism in studied subjects.
Gene Genotype Children number (%) Adult number (%)
FOXO1a Wild type 24 (100) 62 (87)
Homozygous 0 (0) 7 (9.85)
Heterozygous 0 (0) 2 (2.81)
FOXO3a Wild type 19 (82.6) 75 (89.2)
Homozygous 2 (8.69) 7 (8.33)
Heterozygous 2 (8.69) 2 (2.38Two metabolic problems were recognized in our obese
patients when compared to their corresponding healthy con-
trols. These are dyslipidemia and insulin resistance although
these problems were obvious in obese adults than obese chil-
dren. Dyslipidemia was manifested in the form of elevated cho-
lesterol, triglycerides and LDL levels in the obese adult
patients compared to controls. Our results are in agreement
with O¨nal and colleagues who reported dyslipidemia of higher
triglyceride and lower HDL levels in insulin resistant subjects
[15]. This may increase their risk of developing cardiovascular
diseases in the presence of high systolic and diastolic blood
pressure [16].
Insulin resistance was an evident ﬁnding in our obese adults
compared to controls, also a higher fasting insulin level than
normal, although fasting and post prandial blood glucose were
not signiﬁcantly different between the two groups. This may be
due to the release of a high amount of non-esteriﬁed fatty
acids, glycerol hormones and proinﬂammatory cytokines from
adipose tissue [17]. In children there was a signiﬁcant correla-
tion between obese and normal as regards insulin secretion
represented by HOMA-B Index.
In adults resistance to insulin leads ﬁnally to type 2 diabetes
taking into consideration that it has a direct link to changes in
lipid proﬁle in obese patients as proved by Schaefer and his
team [18]. Moreover, the development of type 2 diabetes mel-
litus is induced by the decreased insulin sensitivity, which leads
to increased insulin production. This imbalance causes a pre-
disposition to several metabolic disorders such as early athero-
sclerosis, progressive obesity, acanthosis nigricans, increase in
Table 6 Association of anthropometric characteristics, lipid proﬁles and HOMA with Foxo1a and Foxo3a polymorphisms among
children and adults.
Characteristics Foxo1a Foxo3a
Groups Mean Square P value Groups Mean Square P value
BMI 1 18.9 .789 1 13.7 .849
2 79.6 2 84.0
SBP 1 36.8 .862 1 9.0 .844
2 247.3 2 231.0
DBP 1 29.4 .761 1 15.0 .692
2 107.0 2 94.8
HOMA-IR 1 3.95 .430 1 19.9 .022*
2 4.62 2 4.9
HOMA-B 1 26882.3 .090 1 47532.9 .011*
2 10786.5 2 10000.7
CHOL-T 1 5554.6 .091 1 7988.7 .028*
2 2252.5 2 2145.7
TRIG 1 653.5 .812 1 3718.1 .270
2 3125.4 2 2802.5
HDL-C 1 22.4 .846 1 11.6 .915
2 133.5 2 130.7
LDL-C 1 5336.8 .023* 1 2297.2 .193
2 1342.0 2 1367.7
1: Between groups; 2: within groups.
BMI: body mass index, SBP: systolic blood pressure, DBP: diastolic blood pressure, CHOL-T: total cholesterol, TRIG: triglycerides.
HOMA-IR: homeostatic model assessment-insulin resistance, HOMA-B: homeostatic model assessment-b-cell function.
* Signiﬁcance = P< 0.05.
FOXO genes polymorphism and MS 133skin tags, hypertension, dyslipidemia, fatty liver and polycystic
ovarian syndrome [19].
5. Conclusion
There is an association between FOXO gene mutation, insulin
resistance and secretion and this imbalance is associated with
metabolic syndrome, which includes obesity, insulin resistance,
hyperlipidemia, and hypertension. Our ﬁndings suggest the
utility of the HOMA indexes for assessing insulin resistance
and b-cell function in identifying individuals who are at high
risk and who may beneﬁt from interventions for diabetes
and cardiovascular disease prevention.
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